METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT NEUROPATHY
The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.
1 . A method for treating peripheral neuropathy or hyperalgesia in a subject in need thereof, comprising administering to the subject an effective amount of a peptide having the formula D-Arg-2′6′-dimethyltyrosine-Lys-Phe-NH 2 .
2 . The method of claim 1 , wherein the peripheral neuropathy or hyperalgesia is drug-induced.
3 . The method of claim 2 , wherein the drug is a chemotherapeutic agent.
4 . The method of claim 3 , wherein the chemotherapeutic agent is procarbazine, nitrofurazone, podophyllum, mustine, ethoglucid, cisplatin, suramin, paclitaxel, chlorambucil, altretamine, carboplatin, cytarabine, docetaxel, dacarbazine, etoposide, ifosfamide with mesna, fludarabine, tamoxifen, teniposide, thioguanine, or vincristine.
5 . The method of claim 3 , wherein the chemotherapeutic agent is vincristine.
6 . The method of claim 2 , wherein the peptide is administered simultaneous with the drug.
7 . The method of claim 2 , wherein the peptide is administered subsequent to the drug.
8 . The method of claim 1 , wherein the peripheral neuropathy causes hyperalgesia.
9 . The method of claim 1 , wherein the subject is a human.
10 . The method of claim 1 , wherein the peptide is administered intravenously, orally, subcutaneously, transdermally, intraperitoneally, intrathecally intramuscularly, intranasally, bucally, sublingually, translingually, or topically.
11 . A method for preventing hyperalgesia in a subject in need thereof, comprising administering to the subject an effective amount of a peptide having the formula D-Arg-2′6′-dimethyltyrosine-Lys-Phe-NH 2 .
12 . The method of claim 11 , wherein the hyperalgesia is drug-induced.
13 . The method of claim 12 , wherein the drug is a chemotherapeutic agent.
14 . The method of claim 13 , wherein the chemotherapeutic agent is procarbazine, nitrofurazone, podophyllum, mustine, ethoglucid, cisplatin, suramin, paclitaxel, chlorambucil, altretamine, carboplatin, cytarabine, docetaxel, dacarbazine, etoposide, ifosfamide with mesna, fludarabine, tamoxifen, teniposide, thioguanine, or vincristine.
15 . The method of claim 13 , wherein the chemotherapeutic agent is vincristine.
16 . The method of claim 12 , wherein the peptide is administered simultaneous with the drug.
17 . The method of claim 12 , wherein the peptide is administered subsequent to the drug.
18 . The method of claim 11 , wherein the peptide is administered prior the onset of hyperalgesia.
19 . The method of claim 11 , wherein the subject is a human.
20 . The method of claim 11 , wherein the peptide is administered intravenously, orally, subcutaneously, transdermally, intraperitoneally, intrathecally intramuscularly, intranasally, bucally, sublingually, translingually, or topically.
21 . A composition for treating or preventing hyperalgesia in a subject in need thereof, comprising an effective amount of a peptide having the formula D-Arg-2′6′-dimethyltyrosine-Lys-Phe-NH 2 .
22 . The composition of claim 21 , wherein the hyperalgesia is drug-induced.
23 . The composition of claim 22 , wherein the drug is a chemotherapeutic agent.
24 . The composition of claim 23 , wherein the chemotherapeutic agent is procarbazine, nitrofurazone, podophyllum, mustine, ethoglucid, cisplatin, suramin, paclitaxel, chlorambucil, altretamine, carboplatin, cytarabine, docetaxel, dacarbazine, etoposide, ifosfamide with mesna, fludarabine, tamoxifen, teniposide, thioguanine, or vincristine.
25 . The composition of claim 22 , wherein the chemotherapeutic agent is vincristine.
26 . The composition of claim 22 , wherein the peptide is administered simultaneous with the drug.
27 . The composition of claim 22 , wherein the peptide is administered subsequent to the drug.
28 . The composition of claim 21 , wherein the peptide is administered prior the onset of hyperalgesia.
29 . The composition of claim 21 , wherein the subject is a human.
30 . The composition of claim 21 , wherein the peptide is administered intravenously, orally, subcutaneously, transdermally, intraperitoneally, intrathecally intramuscularly, intranasally, bucally, sublingually, translingually, or topically.